Graceffo Eugenio, Pedersen Elisa, Rosário Marta, Krude Heiko, Schuelke Markus
Department of Neuropediatrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, 13353 Berlin, Germany.
Einstein Center for Neurosciences Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
Int J Mol Sci. 2024 Dec 17;25(24):13512. doi: 10.3390/ijms252413512.
Thyroid hormone receptor alpha (THR) is a nuclear hormone receptor that binds triiodothyronine (T3) and acts as an important transcription factor in development, metabolism, and reproduction. The coding gene, , has two major splicing isoforms in mammals, and , which encode THR1 and THR1, respectively. The better characterized isoform, THR1, is a transcriptional stimulator of genes involved in cell metabolism and growth. The less well-characterized isoform, THR2, lacks the ligand-binding domain (LBD) and may act as an inhibitor of THRα1 activity. Thus, the ratio of THR1 to THR2 isoforms is critical for transcriptional regulation in various tissues and during development and may be abnormal in a number of thyroid hormone resistance syndromes. However, the complete characterization of the THRα isoform expression pattern in healthy human tissues, and especially the study of changes in the ratio of THRα1 to THRα2 in cultured patient cells, has been hampered by the lack of suitable tools to detect the isoform-specific expression patterns. Therefore, we developed a plasmid splicing detector that allows the visualization and quantification of the differential expression of and splicing isoforms in living single cells during time-lapse and perturbation experiments. This tool enables experiments to further characterize the role of THRα2 and to perform high-throughput drug screening. Molecules that modify splicing may be developed into drugs for the treatment of thyroid hormone resistance syndromes.
甲状腺激素受体α(THR)是一种核激素受体,它结合三碘甲状腺原氨酸(T3),并在发育、代谢和生殖过程中作为重要的转录因子发挥作用。编码基因 在哺乳动物中有两种主要的剪接异构体, 和 ,它们分别编码THR1和THR1。特征更明确的异构体THR1是参与细胞代谢和生长的基因的转录激活剂。特征不太明确的异构体THR2缺乏配体结合结构域(LBD),可能作为THRα1活性的抑制剂发挥作用。因此,THR1与THR2异构体的比例对于各种组织以及发育过程中的转录调控至关重要,并且在许多甲状腺激素抵抗综合征中可能异常。然而,由于缺乏检测异构体特异性表达模式的合适工具,健康人体组织中THRα异构体表达模式的完整表征,尤其是培养的患者细胞中THRα1与THRα2比例变化的研究受到了阻碍。因此,我们开发了一种质粒 剪接检测器,它能够在延时和扰动实验期间在活的单细胞中可视化并定量 和 剪接异构体的差异表达。该工具使实验能够进一步表征THRα2的作用,并进行高通量药物筛选。修饰 剪接的分子可能被开发成治疗甲状腺激素抵抗综合征的药物。